ストックスクリーナーアプリを入手
14.54
3.41%
0.48
アフターアワーズ：
14.54
前日終値:
$14.06
開ける：
$14.15
24時間の取引高:
68,226
Relative Volume:
0.31
時価総額：
$544.39M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-1.76%
1か月 パフォーマンス:
+33.39%
6か月 パフォーマンス:
+16.60%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$14.09
$14.62
1週間の範囲:
$13.43
$15.70
52週間の値動き範囲:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
ORKA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
14.54 | 526.41M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-10-11 | 開始されました | Stifel | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | Leerink Partners | Outperform |
| 2024-09-16 | 開始されました | TD Cowen | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2018-02-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 開始されました | Dawson James | Buy |
すべてを表示
Oruka Therapeutics Inc (ORKA) 最新ニュース
What drives Oruka Therapeutics Inc. stock priceOverwhelming financial success - Autocar Professional
Is Oruka Therapeutics Inc. a good long term investmentAccelerated investment success - Autocar Professional
H.C. Wainwright reiterates Buy rating on Oruka Therapeutics stock as FDA clears IND - Investing.com Canada
Oruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug Trial - MSN
Oruka Therapeutics Inc. Stock Analysis and ForecastMassive profits - Autocar Professional
What analysts say about Oruka Therapeutics Inc. stockExponential return rates - jammulinksnews.com
Wedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Announces IND Clearance for EVERLAST-A - GlobeNewswire
Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug - Investing.com India
Stifel reiterates Buy rating on Oruka Therapeutics stock with $47 target - Investing.com Canada
Oruka Therapeutics: Revolutionizing Psoriasis Treatment with Extended-Dosing Biologics - AInvest
FDA clears Oruka’s IND for psoriasis drug ORKA-001 phase 2a trial - Investing.com India
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September - Yahoo Finance
How high can Oruka Therapeutics Inc. stock price go in 2025Balanced Risk Reward Portfolio - Newser
How Oruka Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser
Why Oruka Therapeutics Inc. stock attracts strong analyst attentionFree Real-Time Stock Data - Newser
What makes Oruka Therapeutics Inc. stock price move sharplyWeekly Big Movers - Newser
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Oruka Therapeutics announces COO appointment - MSN
Oruka Therapeutics Shares Soar 16.1% on Executive Promotion, Index Inclusion - AInvest
Oruka Therapeutics Promotes Laura Sandler to COO - MarketScreener
Oruka Therapeutics promotes Laura Sandler to chief operating officer - Investing.com
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer - GlobeNewswire
Oruka Therapeutics Appoints New Chief Operating Officer - TipRanks
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 3000E Index - MarketScreener
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts - Defense World
Wall Street Zen Downgrades Oruka Therapeutics (NASDAQ:ORKA) to Sell - Defense World
Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Inc (ORKA) 財務データ
Oruka Therapeutics Inc (ORKA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
4.91%
0.25%
大文字化:
|
ボリューム (24 時間):